ROIV · Roivant Sciences Ltd.

Summary

Roivant Sciences Ltd. amended its 8-K to file Exhibit 10.1, a Settlement Agreement dated March 3, 2026, between Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd. (solely for certain purposes), and Moderna, Inc. and ModernaTX, Inc., resolving all U.S. and international patent infringement litigations over Genevant/Arbutus’ lipid nanoparticle technology used in Moderna's vaccines.

Key takeaways

• Settlement Agreement effective March 3, 2026, resolves US Litigation (Civil Action No. 1-22-cv-00252-JDW in Delaware District Court) and Ex-US Litigation (Canada T-704-25, Japan 2025 (Wa) 70079, Switzerland O2025 002, UPC cases, EPO oppositions)
• Parties include Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd., Moderna Inc., ModernaTX Inc.
• Covers Asserted US Patents (Nos. 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; 11,141,378) and Asserted Ex-US Patents (Canada 2,721,333; Japan 5,475,753; EP 2279254; EP 4241767)
• Applies to Moderna Licensed Products: SPIKEVAX, mNEXSPIKE, mRESVIA, and other SM-102 LNP mRNA vaccines against infectious diseases
• Mutual releases of all claims related to litigations and patent infringement upon Moderna's noncontingent lump sum payment
• Preserves Moderna's right to appeal §1498 Disputed Matter regarding 493,757,200 Disputed Doses under C-100 Contract